Developments in metastatic pancreatic cancer: is gemcitabine still the standard?

@article{Ying2012DevelopmentsIM,
  title={Developments in metastatic pancreatic cancer: is gemcitabine still the standard?},
  author={Jie-er Ying and Li-ming Zhu and Bi-Xia Liu},
  journal={World journal of gastroenterology},
  year={2012},
  volume={18 8},
  pages={736-45}
}
In the past 15 years, we have seen few therapeutic advances for patients with pancreatic cancer, which is the fourth leading cause of cancer-related death in the United States. Currently, only about 6% of patients with advanced disease respond to standard gemcitabine therapy, and median survival is only about 6 mo. Moreover, phase III trials have shown that adding various cytotoxic and targeted chemotherapeutic agents to gemcitabine has failed to improve overall survival, except in cases in… CONTINUE READING
18 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…